At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ORMP Oramed Pharmaceuticals
Closed 11-22 16:00:00 EST
2.34
+0.03
+1.30%
盘后2.34
+0.000.00%
16:06 EST
High2.39
Low2.30
Vol106.95K
Open2.31
D1 Closing2.31
Amplitude3.89%
Mkt Cap94.33M
Tradable Cap78.76M
Total Shares40.31M
T/O251.10K
T/O Rate0.32%
Tradable Shares33.66M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Oramed Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.